$MIRM
Mirum Pharmaceuticals, Inc. Stock $mirm

$mirm Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000175942524000038 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$90.38M	$47.73M
YoY Change		89.37%	154.13%
Cost Of Revenue		$20.81M	$10.23M
YoY Change		103.38%	248.91%
Gross Profit		$69.57M	$37.50M
YoY Change		85.52%	136.62%
Gross Profit Margin		76.98%	78.58%
Selling, General & Admin		$50.55M	$36.53M
YoY Change		38.37%	62.25%
% of Gross Profit		72.65%	97.41%
Research & Development		$31.71M	$26.12M
YoY Change		21.42%	-0.38%
% of Gross Profit		45.58%	69.65%
Depreciation & Amortization		$6.055M	$2.670M
YoY Change		126.78%	143.61%
% of Gross Profit		8.7%	7.12%
Operating Expenses		$103.1M	$72.87M
YoY Change		41.43%	41.06%
Operating Profit		-$12.68M	-$25.15M
YoY Change		-49.56%	-23.52%
Interest Expense		-$117.0K	$490.0K
YoY Change		-123.88%	-118.71%
% of Operating Profit
Other Income/Expense, Net		-$1.087M	$1.322M
YoY Change		-182.22%	-788.54%
Pretax Income		-$13.89M	-$23.34M
YoY Change		-40.49%	-34.61%
Income Tax		$347.0K	$249.0K
% Of Pretax Income
Net Earnings		-$14.24M	-$23.59M
YoY Change		-39.65%	-33.94%
Net Earnings / Revenue		-15.75%	-49.42%
Basic Earnings Per Share		-$0.30	-$0.57
Diluted Earnings Per Share		-$0.30	-$0.57
COMMON SHARES
Basic Shares Outstanding	48.00M shares	47.71M shares	38.30M
Diluted Shares Outstanding		47.78M shares	41.10M

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$284.4M	$306.0M
YoY Change	-7.05%	65.11%
Cash & Equivalents	$223.0M	$303.1M
Short-Term Investments	$61.48M	$2.971M
Other Short-Term Assets	$12.06M	$12.50M
YoY Change	-3.54%	80.4%
Inventory	$21.59M	$22.25M
Prepaid Expenses
Receivables	$68.53M	$47.83M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$386.6M	$388.6M
YoY Change	-0.5%	80.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.212M	$787.0K
YoY Change	54.0%	-1.01%
Goodwill
YoY Change
Intangibles	$255.8M	$258.3M
YoY Change	-0.98%	473.68%
Long-Term Investments	$9.321M
YoY Change
Other Assets	$5.380M	$1.510M
YoY Change	256.29%	-11.7%
Total Long-Term Assets	$281.3M	$262.1M
YoY Change	7.33%	76.13%
TOTAL ASSETS
Total Short-Term Assets	$386.6M	$388.6M
Total Long-Term Assets	$281.3M	$262.1M
Total Assets	$667.9M	$650.6M
YoY Change	2.65%	78.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.545M	$7.369M
YoY Change	29.53%	-30.14%
Accrued Expenses	$104.7M	$66.21M
YoY Change	58.13%	72.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$115.8M	$74.66M
YoY Change	55.03%	45.27%
LONG-TERM LIABILITIES
Long-Term Debt	$307.7M	$306.0M
YoY Change	0.54%
Other Long-Term Liabilities	$3.972M	$7.000K
YoY Change	56642.86%	-99.84%
Total Long-Term Liabilities	$3.972M	$7.000K
YoY Change	56642.86%	-99.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$115.8M	$74.66M
Total Long-Term Liabilities	$3.972M	$7.000K
Total Liabilities	$435.9M	$381.6M
YoY Change	14.23%	95.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$620.4M	-$520.6M
YoY Change	19.17%	46.07%
Common Stock	$851.5M	$791.1M
YoY Change	7.63%	50.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$232.0M	$269.1M
YoY Change
Total Liabilities & Shareholders Equity	$667.9M	$650.6M
YoY Change	2.65%	78.58%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$14.24M	-$23.59M
YoY Change	-39.65%	-33.94%
Depreciation, Depletion And Amortization	$6.055M	$2.670M
YoY Change	126.78%	143.61%
Cash From Operating Activities	$3.984M	-$18.22M
YoY Change	-121.87%	-29.99%
INVESTING ACTIVITIES
Capital Expenditures	$10.18M	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$7.855M	-$182.8M
YoY Change	-95.7%	129.86%
Cash From Investing Activities	-$18.04M	-$182.8M
YoY Change	-90.13%	129.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.863M	207.1M
YoY Change	-98.13%	140.66%
NET CHANGE
Cash From Operating Activities	3.984M	-18.22M
Cash From Investing Activities	-18.04M	-182.8M
Cash From Financing Activities	3.863M	207.1M
Net Change In Cash	-10.19M	6.150M
YoY Change	-265.67%	-131.56%
FREE CASH FLOW
Cash From Operating Activities	$3.984M	-$18.22M
Capital Expenditures	$10.18M	$0.00
Free Cash Flow	-$6.197M	-$18.22M
YoY Change	-65.99%	-29.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	Mirum Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1281555
	dei	Entity Address Address Line1 EntityAddressAddressLine1	989 East Hillsdale Boulevard
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	222969000	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Foster City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94404
	dei	City Area Code CityAreaCode	650
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	MIRM
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48004582	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	286326000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	61476000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	68530000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67968000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	21594000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	22312000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12057000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10935000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	386626000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	387541000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	425000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	9321000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1212000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	706000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9135000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1284000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	252925000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5380000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4165000	usd
CY2024Q3	us-gaap	Assets Assets	667893000	usd
CY2023Q4	us-gaap	Assets Assets	646621000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9545000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7416000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	104700000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78544000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1104000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	115751000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	87064000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8480000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	617000	usd
CY2024Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	307666000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	306421000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3972000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3849000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	435869000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	397951000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47968121	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47968121	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46723143	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46723143	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	851490000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	803260000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-620391000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-556239000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	920000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1644000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	232024000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	248670000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	667893000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	646621000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90377000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47725000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	237474000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	116820000	usd
CY2024Q3	mirm	Cost Of Sales CostOfSales	20806000	usd
CY2023Q3	mirm	Cost Of Sales CostOfSales	10228000	usd
	mirm	Cost Of Sales CostOfSales	58863000	usd
	mirm	Cost Of Sales CostOfSales	22019000	usd
CY2024Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	31710000	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	26117000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	71674000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	50545000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36528000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	145391000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	99696000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	103061000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	72873000	usd
	us-gaap	Operating Expenses OperatingExpenses	300858000	usd
	us-gaap	Operating Expenses OperatingExpenses	193389000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12684000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-25148000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-63384000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-76569000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3469000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4061000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	10588000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9960000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3574000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10732000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	11542000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49076000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1087000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1322000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	982000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	237000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13888000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23339000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-62546000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-126990000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	347000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	249000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1606000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	766000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14235000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-23588000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-64152000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-127756000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47316789	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38973060	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38973060	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-23588000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-64152000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-127756000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	291000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	11000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	298000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	230000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1106000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1545000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1022000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1471000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12838000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25122000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64876000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-128997000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	248670000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11664000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-25279000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-1657000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	234603000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12196000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-24638000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-464000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	228988000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	223394000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001759425
	dei	Local Phone Number LocalPhoneNumber	667-4085
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	255794000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1506000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	96604000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3586000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.28
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47782619	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47782619	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41098920	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41098920	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47316789	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14235000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12011000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14235000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	1397000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	232024000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	142037000	usd
CY2023Q1	mirm	Stock Issued During Period Value Contingent Milestone Achievement StockIssuedDuringPeriodValueContingentMilestoneAchievement	4292000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8728000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30130000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	353000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	141150000	usd
CY2023Q2	mirm	Stock Issued During Period Value Indemnification Holdback Liability StockIssuedDuringPeriodValueIndemnificationHoldbackLiability	896000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8565000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-74038000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-60000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	78610000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8588000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-23588000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-1534000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	269081000	usd
	us-gaap	Profit Loss ProfitLoss	-64152000	usd
	us-gaap	Profit Loss ProfitLoss	-127756000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	35193000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	25303000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17573000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5335000	usd
	mirm	Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity InventoryReservesAndFirmPurchaseCommitmentLossesUnderOperatingActivity	-1783000	usd
	mirm	Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity InventoryReservesAndFirmPurchaseCommitmentLossesUnderOperatingActivity	-1491000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1245000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	718000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49076000	usd
	mirm	Non Cash Interest Expense On Revenue Interest Purchase Agreement NonCashInterestExpenseOnRevenueInterestPurchaseAgreement	0	usd
	mirm	Non Cash Interest Expense On Revenue Interest Purchase Agreement NonCashInterestExpenseOnRevenueInterestPurchaseAgreement	5060000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1082000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1230000	usd
	mirm	Non Cash Lease Expense NonCashLeaseExpense	985000	usd
	mirm	Non Cash Lease Expense NonCashLeaseExpense	476000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	425000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1025000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	562000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23840000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1122000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3447000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2952000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2206000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1496000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-180000	usd
	mirm	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	30973000	usd
	mirm	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	18250000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-568000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-711000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15393000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54326000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	77543000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	27329000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	7750000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	150000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	973000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	109000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	212762000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	20000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-90766000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-105200000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	202363000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14480000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	305304000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12359000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8253000	usd
	mirm	Repayment Of Revenue Interest RepaymentOfRevenueInterest	0	usd
	mirm	Repayment Of Revenue Interest RepaymentOfRevenueInterest	-195577000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12359000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	334823000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	82000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-241000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-62932000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	175056000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	286326000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	128003000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	303059000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	881000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	824000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6325000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	771000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	mirm	Accrued Milestone Payments Classified As Intangible Assets Net AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet	0	usd
	mirm	Accrued Milestone Payments Classified As Intangible Assets Net AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet	5000000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9633000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	473000	usd
	mirm	Right Of Use Asset And Lease Liabilities Decrease Due To Lease Modification RightOfUseAssetAndLeaseLiabilitiesDecreaseDueToLeaseModification	723000	usd
	mirm	Right Of Use Asset And Lease Liabilities Decrease Due To Lease Modification RightOfUseAssetAndLeaseLiabilitiesDecreaseDueToLeaseModification	0	usd
	mirm	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	909000	usd
	mirm	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	578000	usd
	mirm	Stock Issued During Period Value Contingent Milestone Achievement StockIssuedDuringPeriodValueContingentMilestoneAchievement	0	usd
	mirm	Stock Issued During Period Value Contingent Milestone Achievement StockIssuedDuringPeriodValueContingentMilestoneAchievement	5188000	usd
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2018-05-02
	mirm	Number Of Approved Medicines NumberOfApprovedMedicines	3	medicine
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-620400000	usd
CY2024Q3	us-gaap	Investments And Cash InvestmentsAndCash	293800000	usd
CY2024Q3	us-gaap	Investments And Cash InvestmentsAndCash	293800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited condensed consolidated financial statements as of and for the three and nine months ended September 30, 2024 reflect the Company’s estimates of the impact of the geopolitical and macroeconomic environment, including the impact of inflation, bank failures, high interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></div>
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	222969000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	303059000	usd
CY2024Q3	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	425000	usd
CY2023Q3	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	0	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	223394000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	303059000	usd
	mirm	Investments Classified As Cash And Cash Equivalent Original Maturities InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities	P3M
	mirm	Fair Value Of Its Investments Related To Credit Loss FairValueOfItsInvestmentsRelatedToCreditLoss	0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	mirm	Purchase Commitments PurchaseCommitments	5900000	usd
CY2023	mirm	Purchase Commitments PurchaseCommitments	5200000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	286590000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	30796000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	255794000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y3M18D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	266590000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13665000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	252925000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P12Y3M18D
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5900000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17100000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2600000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5100000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5975000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	23898000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	23791000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	23575000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	23575000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	154980000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	255794000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90377000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47725000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	237474000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	116820000	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1000000.0	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1100000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1400000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1200000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21886617	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20828610	shares
CY2024Q3	mirm	Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	266322000	usd
CY2024Q3	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	300000	usd
CY2024Q3	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	usd
CY2024Q3	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	266620000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	195823000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	61476000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	9321000	usd
CY2024Q3	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	266620000	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	278116000	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	278116000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	278116000	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	278116000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	61476000	usd
CY2024Q3	mirm	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One And Two DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneAndTwo	9321000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	70797000	usd
CY2024Q3	mirm	Available For Sale Securities Gross Realized Gain Loss Net1 AvailableForSaleSecuritiesGrossRealizedGainLossNet1	0	usd
CY2023Q3	mirm	Available For Sale Securities Gross Realized Gain Loss Net1 AvailableForSaleSecuritiesGrossRealizedGainLossNet1	0	usd
	mirm	Available For Sale Securities Gross Realized Gain Loss Net1 AvailableForSaleSecuritiesGrossRealizedGainLossNet1	0	usd
	mirm	Available For Sale Securities Gross Realized Gain Loss Net1 AvailableForSaleSecuritiesGrossRealizedGainLossNet1	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2790000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2998000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	14258000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9873000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4546000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9441000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	21594000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	22312000	usd
CY2024Q3	mirm	Accrued Sales Deductions Current AccruedSalesDeductionsCurrent	40591000	usd
CY2023Q4	mirm	Accrued Sales Deductions Current AccruedSalesDeductionsCurrent	23650000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23077000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20939000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	11851000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7941000	usd
CY2024Q3	mirm	Accrued Contract Manufacturing And Non Clinical Costs Current AccruedContractManufacturingAndNonClinicalCostsCurrent	8560000	usd
CY2023Q4	mirm	Accrued Contract Manufacturing And Non Clinical Costs Current AccruedContractManufacturingAndNonClinicalCostsCurrent	9922000	usd
CY2024Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8637000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6716000	usd
CY2024Q3	mirm	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	6713000	usd
CY2023Q4	mirm	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	7268000	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	5271000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2108000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	104700000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78544000	usd
CY2023Q2	mirm	Stock Issued During Period Shares Indemnification Holdback Liability StockIssuedDuringPeriodSharesIndemnificationHoldbackLiability	31631	shares
CY2019Q1	us-gaap	Area Of Land AreaOfLand	5600	sqft
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q1	mirm	Tenant Improvement Allowance TenantImprovementAllowance	400000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M24D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	415000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2380000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2442000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2507000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2512000	usd
CY2024Q3	mirm	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1699000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11955000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1969000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	9986000	usd
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
CY2020Q3	mirm	Maximum Amount Of Sale Covered In Shelf Registration Statement MaximumAmountOfSaleCoveredInShelfRegistrationStatement	300000000.0	usd
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	25703580	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	24145170	shares
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11908000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8385000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35193000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25303000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	200000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	200000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	900000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	600000	usd

Files In Submission

Name	View Source	Status
0001759425-24-000038-index-headers.html	Edgar Link	pending
0001759425-24-000038-index.html	Edgar Link	pending
0001759425-24-000038.txt	Edgar Link	pending
0001759425-24-000038-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mirm-10qq324xexx311.htm	Edgar Link	pending
mirm-10qq324xexx312.htm	Edgar Link	pending
mirm-10qq324xexx321.htm	Edgar Link	pending
mirm-10qq324xexx322.htm	Edgar Link	pending
mirm-20240930.htm	Edgar Link	pending
mirm-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mirm-20240930_def.xml	Edgar Link	unprocessable
mirm-20240930_cal.xml	Edgar Link	unprocessable
mirm-20240930_lab.xml	Edgar Link	unprocessable
mirm-20240930_pre.xml	Edgar Link	unprocessable
mirm-20240930_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MIRM
Mirum Pharmaceuticals, Inc. Stock $mirm

2024 Q4 Form 10-Q Financial Statement

#000175942524000038 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MIRM Mirum Pharmaceuticals, Inc. Stock $mirm

2024 Q4 Form 10-Q Financial Statement

#000175942524000038 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MIRM
Mirum Pharmaceuticals, Inc. Stock $mirm